Abivax S.A. Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities
Abivax S.A. (ABVX) reported Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities of EUR 36.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities · last filed 2026-03-23
- Abivax S.A. increase decrease through changes in fair values liabilities arising from financing activities for the quarter ending 2025-12-31 was 0.00 EUR, a 100.00% decline year-over-year.
- Abivax S.A. increase decrease through changes in fair values liabilities arising from financing activities for the quarter ending 2025-09-30 was 37.34M EUR, a 5234.43% increase year-over-year.
- Abivax S.A. increase decrease through changes in fair values liabilities arising from financing activities for the quarter ending 2025-06-30 was -2.39M EUR.
- Abivax S.A. increase decrease through changes in fair values liabilities arising from financing activities for the quarter ending 2025-03-31 was 1.05M EUR, a 48.07% decline year-over-year.
| Period end | Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities 3 month | Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities 6 month | Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities 9 month | Increase Decrease Through Changes In Fair Values Liabilities Arising From Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-23 | 37.34M EUR derived: sum of 2 quarters · filed 2026-03-23 | 34.95M EUR derived: sum of 3 quarters · filed 2026-03-23 | 36.00M EUR 20-F · filed 2026-03-23 |
| 2025-09-30 | 37.34M EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-12-15 | 34.95M EUR derived: sum of 2 quarters · filed 2025-12-15 | 36.00M EUR 6-K · filed 2025-12-15 | 36.76M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-06-30 | -2.39M EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-09-08 | -1.34M EUR 6-K · filed 2025-09-08 | -581.00K EUR derived: sum of 3 quarters · filed 2026-03-23 | 119.00K EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-03-31 | 1.05M EUR 6-K · filed 2025-06-02 | 1.81M EUR derived: sum of 2 quarters · filed 2026-03-23 | 2.51M EUR derived: sum of 3 quarters · filed 2026-03-23 | 394.00K EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-12-31 | 758.00K EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-23 | 1.46M EUR derived: sum of 2 quarters · filed 2026-03-23 | -657.00K EUR derived: sum of 3 quarters · filed 2026-03-23 | 1.37M EUR 20-F · filed 2026-03-23 |
| 2024-09-30 | 700.00K EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-12-15 | -1.42M EUR derived: sum of 2 quarters · filed 2025-12-15 | 609.00K EUR 6-K · filed 2025-12-15 | |
| 2024-06-30 | -2.12M EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-09-08 | -91.00K EUR 6-K · filed 2025-09-08 | ||
| 2024-03-31 | 2.02M EUR 6-K · filed 2025-06-02 | |||
| 2023-12-31 | -3.20M EUR 20-F · filed 2026-03-23 | |||
| 2022-12-31 | -1.45M EUR 20-F · filed 2025-03-24 |